Hydroxyapatite/poly(epsilon-caprolactone) composite coatings on hydroxyapatite porous bone scaffold for drug delivery.

Porous hydroxyapatite for artificial bone applications

New processing approaches in calcium phosphate cements and their applications in regenerative medicine.

The purpose of this study is to improve hydroxyapatite (HA) porous scaffolds via coating with biological polymer-HA hybrids for use as wound healing and tissue regeneration Highly porous HA scaffolds, fabricated by a polyurethane foam reticulate method, were coated with hybrid coating solution, consisting of poly(e-caprolactone) (PCL), HA powders, and the antibiotic Vancomycin The PCL to HA ratio was fixed at 15 and the drug amounts were varied [drug/(PCL + HA) = 002 and 004] For the purpose of comparison, bare HA scaffold without the hybrid coating layer was also loaded with Vancomycin via an immersion-adsorption method The hybrid coating structure and morphology were observed with Fourier transformed infrared (FT-IR) spectroscopy and scanning electron microscopy (SEM) The effects of the hybrid coating on the compressive mechanical properties and the in vitro drug release of the scaffolds were investigated in comparison with bare HA scaffold The PCL-HA hybrid coating altered the scaffold pore structure slightly, resulting in thicker stems and reduced porosity With the hybrid coating, the HA scaffold responded to an applied compressive stress more effectively without showing a brittle failure This was attributed to the shielding and covering of the framework surface by the coating layer The encapsulated drugs within the coated scaffold was released in a highly sustained manner as compared to the rapid release of drugs directly adsorbed on the pure HA scaffold These findings suggest that the coated HA scaffolds expand their applicability in hard tissue regeneration and wound healing substitutes delivering bioactive molecules

Elena V. Koplik

Papers

A method to fabricate porous spherical hydroxyapatite granules intended for time-controlled drug release.